3 7 5 1 8

论文已发表


注册即可获取德孚的最新动态



IF 收录期刊





更多详情 >>



会员计划

我们很高兴为机构提供一种切实的方法以支持开放获取并鼓励教师和研究人员通过开放获取模式尽可能广泛地传播他们的作品。

更多详情 >>

 

加入德孚官方微信,即可享受论文费用7.5折

已发表论文

HES1  启动子低甲基化对结直肠癌患者的临床病理意义

 

Authors Wu Y, Gong L, Xu J, Mou Y, Xu X, Qian Z

Received 16 September 2017

Accepted for publication 6 November 2017

Published 8 December 2017 Volume 2017:10 Pages 5827—5834

DOI https://doi.org/10.2147/OTT.S151857

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Akshita Wason

Peer reviewer comments 2

Editor who approved publication: Prof. Dr. Geoffrey Pietersz

Abstract: Hairy/enhancer of split 1 (HES1) is a basic helix–loop–helix transcriptional repressor. Aberrant demethylation has been considered a common mechanism of tumor promoter gene activation. In the current study, we aimed to investigate the methylation status of the HES1  promoter and correlations with clinicopathological parameters and prognosis in colorectal cancer (CRC). The expression of HES1 in 50 paired CRC specimens and adjacent normal tissues was determined by using quantitative real-time polymerase chain reaction and immunohistochemical analysis. Moreover, DNA methylation status was evaluated through methylation-specific polymerase chain reaction and bisulfite sequencing. The correlation of methylation status with HES1 expression level and clinicopathological parameters was statistically analyzed in CRC patients. Our data showed that the methylation level of HES1  was significantly decreased and negatively correlated with HES1 expression in CRC tissues. Moreover, HES1  hypomethylation was associated with a poor histological grade, Dukes’ classification, lymph node metastasis, and clinical stages (<0.05). Furthermore, survival analyses revealed that a decreased methylation status of HES1  was linked to poor prognosis of CRC patients. In conclusion, promoter hypomethylation upregulates HES1 expression and plays a critical role in the progression and prognosis of CRC patients.
Keywords: colorectal cancer, HES1 , hypomethylation, prognosis, progression